Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 3, 1996, Pages 609-612

  Ayestarán, Ana ^a   López, Rosa M ^a   Montoro, José B ^a   Estíbalez, Antero ^a   Pou, Leonor ^a   Julià, Antoni ^a   López, Andrés ^a   Pascual, Begoña ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; INTRALIPID; LIPID EMULSION; METHYLPREDNISOLONE; PETHIDINE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN RESIDENCE TIME; MYCOSIS; NEUTROPENIA; PHARMACOKINETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 0029965353     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.3.609     Document Type: Article

References (18)

1. Brajtburg, J., W. G. Powderly, G. S. Kobayashi, and G. Medoff. 1990 Amphotericin B: delivery systems Antimicrob. Agents Chemother 34:381-384
2. Caillot, D., O. Casasnovas, E. Solary, P. Chavanet, B. Bonnotte, G. Reny, F. Entezam, J. Lopez, A. Bonnin, and H. Guy. 1993. Efficacy and tolerance of an amphotericin B lipid (intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J. Antimicrob. Chemother. 31:161-169.
3. Chavanet, P., N. Charlier, A. Brenet, A. Goux, E. Muggéo, D. Caillot, O. Casasnovas, J. P. Kistermann, A. Waldner, and H. Portier. 1992 Emulsion de l'amphotericine B dans l'intralipide 20%: efficacité in vitro et in vivo Pathol Biol. 40:507-512.
4. Chavanet, P. Y., I. Garry, N. Charlier, D. Caillot, J. P. Kisterman, M. D'Athis, and H. Portier. 1992. Trial of glucose versus fat emulsion in preparation of amphotericin B for use in HIV infected patients with candidiasis Br. Med J. 305:921-925.
5. Ellis, M. E., A. A. Al-Hokail, and H. M. Clark. 1991. A study of rapid vs slow infusion of amphotericin B on toxicity. tolerance and efficacy, abstr. 744, p. 223. In Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington, D.C
6. Estíbalez, A., A. López, A. Julià, J. Bueno, J. Zuazo, and I. Massagué. 1988 Comparison of two forms of amphotericin B administration in neutropenic cancer patients. In Abstracts of the International Conference on Supportive Care in Oncology. UICC, Geneva
7. Gallis, H., R. Drew, and W. Pickard. 1990. Amphotericin B: 30 years of clinical experience Rev. Infect. Dis 12:308-328
8. Gates, C., and R. J. Pinney. 1993. Amphotericin B and its delivery by liposomal and lipid formulations J Clin. Pharm Ther 18:147-253
9. Granich, G. G., G. S. Kobayashi, and D. J. Krogstad. 1986 Sensitive high-pressure liquid chromatographic assay for amphotericin B which incorporates an internal standard. Antimicrob. Agents Chemother 29:584-588.
10. Heinemann, V., B. Kähny, A. Debus, W. Wachholz, and U. Jehn. 1994. Pharmacokinetics of liposomal amphotericin B (Ambisome) vs other lipid based formulations. Bone Marrow Transplant. 14(Suppl. 5):S8-S9
11. Janknegt, R., S. De Marie, I. A. J. M. Bakker-Woundenberg, and D. J. A. Crommelin. 1992. Liposomal and lipid formulations of amphoteriem B. Clin Pharmacokinet. 23:279-291
12. Janoff, A. S. 1990. Liposomes and lipid structures as carriers of amphotericin B. Eur. J. Clin. Microbiol. Infect. Dis. 9:146-151.
13. Janoff, A. S., L. T. Boni, M. C. Popescu, S. R. Minchey, P. R. Cullis, T. D. Madden, T. Taraschi, S. M. Gruner, E. Shyamsunder, M. W. Tate, R. Mendelsohn, and D. Bonner. 1988 Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl. Acad. Sci. USA 85:6122-6126.
14. Kan, V. L., J. E. Bennett, M. A. Amantea, M. C. Smolskis, E. McManus, D. M. Grasela, and J. W. Sherman. 1991. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers J. Infect. Dis. 164:418-421.
15. Kirsh, R., J. Goldstein, J. Tarloff, D. Parris, J. Hook, N. Hanna, P. Bugelski. and G. Poste. 1988. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J. Infect. Dis 158:1065-1070.
16. Moreau, P., N. Milpied, N. Fayette, J. F. Ramée, and J. L. Harousseau. 1992. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed Intralipid compared with conventional amphotericin B in neutropenic patients J. Antimicrob. Chemother. 30:535-541.
17. Sanders, S. W., K. N. Buchi, M. S. Goddard, J. K. Lang, and K. G. Tolman. 1991. Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob. Agents Chemother 35:1029-1034.
18. Van Etten, E. W. M., N. E. Van de Rhee, M. Van Kampen, and I. A. J. M. Bakker-Woundenberg. 1991. Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans. Antimicrob. Agents Chemother. 35:2275-2281